Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the ...
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value ...
The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.
In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...
Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...
Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...
Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...
Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban on imports of its genetic sequencing instruments.
TD Cowen analyst Daniel Brennan maintained a Hold rating on Illumina (ILMN – Research Report) today and set a price target of $140.00. The ...
Beijing banned imports of Illumina’s gene-sequencing machines in response to U.S. tariffs.
Illumina lowered its adjusted profit outlook and cut spending cost for 2025 as the company grapples with Chinese ban on its ...
Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results